Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Down 91.8% in August

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the target of a large drop in short interest in August. As of August 14th, there was short interest totaling 39 shares, a drop of 91.8% from the July 30th total of 474 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.

Basilea Pharmaceutica Price Performance

Shares of OTCMKTS BPMUF remained flat at $77.40 during midday trading on Tuesday. Basilea Pharmaceutica has a 52-week low of $59.29 and a 52-week high of $77.40. The stock’s 50 day simple moving average is $63.19 and its 200 day simple moving average is $66.89. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.68 and a current ratio of 5.11.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.

Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.